Andreas Schwarting

Andreas Schwarting

Helmholtz Institut Mainz - Mainz / Germany
Others
AD Scientific Index ID: 1760363
Helmholtz Institute Mainz
person_outline Andreas Schwarting's MOST POPULAR ARTICLES
1-) A phase III, randomized, placebo‐controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusR Furie, M Petri, O Zamani, R Cervera, DJ Wallace, D Tegzová, ...Arthritis & Rheumatism 63 (12), 3918-3930, 201114722011
2-) Monocyte Chemoattractant Protein 1–Dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in Mrl-Faslpr MiceGH Tesch, S Maifert, A Schwarting, BJ Rollins, VR KelleyThe Journal of Experimental Medicine 190 (12), 1813-1824, 19993681999
3-) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty‐two–week randomized, double‐blind, placebo‐controlled studyW Stohl, A Schwarting, M Okada, M Scheinberg, A Doria, AE Hammer, ...Arthritis & Rheumatology 69 (5), 1016-1027, 20173572017
4-) Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritisGH Tesch, A Schwarting, K Kinoshita, HY Lan, BJ Rollins, VR KelleyThe Journal of clinical investigation 103 (1), 73-80, 19993501999
5-) The Mainz Severity Score Index: a new instrument for quantifying the Anderson–Fabry disease phenotype, and the response of patients to enzyme replacement therapyC Whybra, C Kampmann, F Krummenauer, M Ries, E Mengel, E Miebach, ...Clinical genetics 65 (4), 299-307, 20043142004